The gene therapy market is projected to be worth USD 14.6 billion in 2030- Roots Analysis'

ellaturner

289
views

The gene therapy market is projected to be worth USD 14.6 billion in 2030- Roots Analysis'

Driven by the potential to treat the root cause of diseases, including rare clinical conditions and those that were previously deemed incurable, the gene therapies pipeline is growing, and the market anticipated to witness substantial growth, till 2030

Roots Analysis has announced the addition of “Gene Therapy Market (4th Edition), 2020-2030” report toits list of offerings.

Successof approved gene therapies has resulted in a surge in interest ofbiopharmaceutical developers in this rapidly evolving domain. Presently, theability of gene therapies to treat diverse disease indications is consideredamong the most prominent drivers of this market. In addition, promisingclinical results of pipeline candidates are anticipated to draw in moreinvestments to support product development initiatives.

To order this 720+ page report, which features 220+ figuresand 375+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html

Key Market Insights

Around 800 genetherapies are currently being developed across different stages

Apartfrom 10 approved products, most of the aforementioned therapies (65%) are inthe early stages of development (discovery / preclinical), while the rest arebeing evaluated in clinical trials. It is worth mentioning that more than 40%of clinical stage candidates are intended for the treatment of oncologicaldisorders.

Over 65% of innovatorcompanies focused on gene therapy development, are based in North America

Interestingly,more than 75 players based in the same region, are start-ups, while over 35 aremid-sized players, and 10 are large and very large firms. Since the majority ofgene therapy developers are headquartered in the US, it is considered a keyR&D hub for such advanced therapy medicinal products.

There are 400+registered gene therapy focused clinical trials, worldwide

Clinicalresearch activity, in terms of number of trials registered, is reported to haveincreased at a CAGR of 12% during the period 2015-2020. Of the total number oftrials, close to 25% have already been completed, and 35% claim to be activelyrecruiting.

USD 25.4 billion has been invested by both private andpublic investors, since 2015

Sofar, a significant proportion of the capital raised has been through secondaryofferings (USD 12.9 billion). On the other hand, around USD 5 billion wasinvested by venture capital investors, representing 20% of the total amount.

Close to 20,000 patents have been filed / published relatedto gene therapies, since 2016

Around30% of the total number of applications were related to gene editing-basedtherapies, while the remaining were associated with gene therapies. Further,majority of the patent assignees were industry players, however, thecontribution of non-industry players in the overall patent filing activity hasincreased considerably (CAGR of 16%), over the past few years.

There have been several mergers and acquisitions in thismarket during the period 2015-2019

Infact, M&A activity is reported to have increased at a CAGR of more than40%. Key drivers of the acquisitions mentioned in the report include,therapeutic area expansion, access to a novel technology / platform, drug classconsolidation and drug class expansion.

North America andEurope are anticipated to capture over 90% of the market share, in terms ofsales revenues, in 2030

In vivo genetherapies currently represent a significant share of the market, and this trendis unlikely to change in the foreseen future, as several such candidates arebeing evaluated in late stages. In addition, more than 130,000+ patients areprojected to use gene therapies in 2030 and the demand for gene therapies isexpected to grow at an annualized rate of 29% and 31% during the periods2020-2025 and 2025-2030, respectively.

To request a sample copy / brochure of this report, pleasevisit this- https://www.rootsanalysis.com/reports/268/request-sample.html

Key QuestionsAnswered

§ Whoare the leading players engaged in the development of gene therapies?

§ Howmany gene therapies are presently being evaluated across different stages ofdevelopment?

§ Whatare various diseases targeted by gene therapies?

§ Whatare the key technology platforms that are either available, or being developed forgene therapy discovery and production?

§ Whatkind of vectors are commonly used for the delivery of gene therapies?

§ Whatare the key regulatory guidelines governing the approval of gene therapies,across various geographies?

§ Whatkind of pricing models and reimbursement strategies are currently used by genetherapy developers?

§ Whatkind of contract services are offered related to gene therapies? Who are thekey players in this market?

§ Whatare the drivers of the M&A activity in this market?

§ Whatkind of investors have stake in the gene therapy market?

§ Whatkind of commercialization strategies are used by gene therapy developers?

§ How is the currentand future market opportunity likely to be distributed across key marketsegments?

The USD 14.6billion (by 2030) financial opportunity within the gene therapy market has beenanalyzed across the following segments:

§ Therapeutic approach

§ Gene augmentation

§ Oncolytic therapy

§ Immunotherapy

Others

§ Type of gene therapy

§ Exvivo

§ Invivo

§ Type of vector used

§ Adeno associatedvirus

§ Adenovirus

§ Herpes simplex virus

§ Lentivirus

§ Plasmid DNA

§ Retrovirus

Others

§ Key therapeutic areas

Autoimmune disorders
Cardiovascular diseases
Dermatological disorders
Genetic disorders
Hematological disorders
Metabolic disorders
Muscle-related diseases
Oncological disorders
Ophthalmic diseases
Others

§ Route of administration

§ Intraarticular

§ Intracerebellar

§ Intradermal

§ Intramuscular

§ Intratumoral

§ Intravenous

§ Intravesical

§ Intravitreal

§ Subretinal

Others

§ Key geographicalregions

North America
Europe
Asia-Pacific

The report features inputs from eminent industrystakeholders, according to whom, gene therapies exhibit the potential to becomea promising alternative for the treatment of genetic disorders. The reportincludes detailed transcripts of discussions held with the following experts:

§ Adam Rogers (CEO,Hemera Biosciences)

§ Al Hawkins (CEO, MiloBiotechnology)

§ Buel Dan Rodgers(Founder & CEO, AAVogen)

§ Christopher Reinhard(CEO & Chairman, Gene Therapeutics (previously known as CardiumTherapeutics))

§ Michael Triplett (ex-CEO,Myonexus Therapeutics)

§ Robert Jan Lamers (ex-CEO,Arthrogen)

§ Ryo Kubota (CEO,Chairman & President, Acucela)

§ Tom Wilton (ex-CBO,LogicBio Therapeutics)

§ Jeffrey Hung (CCO,Vigene Biosciences)

§ Cedric Szpirer(Executive & Scientific Director, Delphi Genetics)

§ Marco Schmeer(Project Manager) and Tatjana Buchholz (ex-Marketing Manager, PlasmidFactory)

§ Molly Cameron(Corporate Communications Manager, Orchard Therapeutics)

The research includes brief profiles of key players (listedbelow) engaged in the development of gene therapies; each profile features anoverview of the therapy, current development status, clinical trials and itsresults (if available), target indication, route of administration, andrecent developments (if available).

§ Abeona Therapeutics

§ Advantagene

§ Biogen

§ bluebird bio

§ Castle CreekBiosciences

§ CG Oncology

§ FerGene

§ Freeline Therapeutics

§ Gradalis

§ Helixmith

§ InovioPharmaceuticals

§ Kolon TissueGene